Safety Profile of Nulojix in Home Infusion Settings

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02500498

Enrollment

Registered

2015-07-16

Start date

2014-10-31

Completion date

2015-06-30

Last updated

2015-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The study is a retrospective cohort study that utilizes medical records from the BiologicTx. Data accrual starts upon initial home infusion nurse visit until the most recent home infusion nurse visit. Infusion related adverse events are quantified as number of patients with adverse event over the total number of patients and number of event over total number of home infusion visits.

Interventions

DRUGNulojix

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All adult kidney-only transplant recipients currently receiving NULOJIX in BiologicTx home infusion service settings

Design outcomes

Primary

Measure	Time frame
Proportion of infusion related serious adverse events in adult kidney-only transplant recipients who are treated with belatacept in home infusion settings	24 hours after the date of a home infusion visit

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026